April Fitzsimmons Eichler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 24 | 2024 | 9030 | 0.900 |
Why?
|
Neurotoxicity Syndromes | 2 | 2023 | 300 | 0.380 |
Why?
|
Oligodendroglioma | 4 | 2014 | 279 | 0.350 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 916 | 0.340 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 162 | 0.340 |
Why?
|
Neoplasm Metastasis | 2 | 2012 | 4908 | 0.320 |
Why?
|
Insurance Claim Reporting | 1 | 2009 | 166 | 0.310 |
Why?
|
Lymphoma | 4 | 2023 | 1901 | 0.310 |
Why?
|
Carcinoma, Ductal | 1 | 2008 | 97 | 0.300 |
Why?
|
Chromosomes, Human, Pair 1 | 4 | 2014 | 637 | 0.270 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2020 | 1374 | 0.270 |
Why?
|
Blood-Brain Barrier | 2 | 2013 | 1025 | 0.250 |
Why?
|
Receptor, erbB-2 | 3 | 2013 | 2556 | 0.250 |
Why?
|
Glioblastoma | 6 | 2018 | 3482 | 0.230 |
Why?
|
Carcinoma, Lobular | 1 | 2008 | 481 | 0.220 |
Why?
|
Combined Modality Therapy | 6 | 2018 | 8526 | 0.210 |
Why?
|
Meningeal Neoplasms | 2 | 2022 | 1248 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2020 | 9275 | 0.200 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 63 | 0.190 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2010 | 5303 | 0.190 |
Why?
|
Quinazolines | 5 | 2014 | 1371 | 0.180 |
Why?
|
Antineoplastic Agents | 7 | 2014 | 13635 | 0.180 |
Why?
|
Methotrexate | 1 | 2007 | 1720 | 0.180 |
Why?
|
Videotape Recording | 2 | 2012 | 337 | 0.170 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2527 | 0.160 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2012 | 664 | 0.150 |
Why?
|
Chromosome Deletion | 2 | 2014 | 1387 | 0.140 |
Why?
|
Dacarbazine | 4 | 2013 | 559 | 0.140 |
Why?
|
Lung Neoplasms | 3 | 2010 | 13333 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11735 | 0.140 |
Why?
|
Breast Neoplasms | 7 | 2014 | 21009 | 0.120 |
Why?
|
Epothilones | 1 | 2014 | 42 | 0.110 |
Why?
|
Glioma | 3 | 2016 | 3455 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 2 | 2013 | 2047 | 0.110 |
Why?
|
Meningioma | 1 | 2022 | 1218 | 0.110 |
Why?
|
Prognosis | 9 | 2024 | 29588 | 0.100 |
Why?
|
Benzamides | 1 | 2018 | 1370 | 0.100 |
Why?
|
Maximum Tolerated Dose | 4 | 2020 | 883 | 0.100 |
Why?
|
Decision Trees | 1 | 2014 | 504 | 0.100 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2012 | 349 | 0.100 |
Why?
|
Neoplasm Staging | 6 | 2014 | 11098 | 0.100 |
Why?
|
Hereditary Central Nervous System Demyelinating Diseases | 1 | 2009 | 42 | 0.080 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 1704 | 0.080 |
Why?
|
Radiotherapy | 3 | 2011 | 1499 | 0.080 |
Why?
|
Terminal Care | 2 | 2012 | 1760 | 0.080 |
Why?
|
Bone Marrow Neoplasms | 2 | 2000 | 101 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5297 | 0.080 |
Why?
|
Melanoma | 2 | 2023 | 5706 | 0.080 |
Why?
|
Survival Rate | 6 | 2014 | 12710 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2012 | 617 | 0.080 |
Why?
|
Gene Amplification | 1 | 2012 | 1086 | 0.070 |
Why?
|
Neoplasms | 3 | 2012 | 22158 | 0.070 |
Why?
|
Phthalazines | 1 | 2010 | 382 | 0.070 |
Why?
|
Patient Preference | 2 | 2012 | 926 | 0.070 |
Why?
|
Middle Aged | 21 | 2024 | 220774 | 0.070 |
Why?
|
Cardiopulmonary Resuscitation | 2 | 2012 | 992 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 3 | 2013 | 5665 | 0.070 |
Why?
|
Mutation | 2 | 2016 | 30044 | 0.070 |
Why?
|
Humans | 36 | 2024 | 761326 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2821 | 0.070 |
Why?
|
Aneuploidy | 1 | 2009 | 551 | 0.060 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3873 | 0.060 |
Why?
|
Paclitaxel | 1 | 2013 | 1732 | 0.060 |
Why?
|
Central Nervous System | 2 | 2023 | 1337 | 0.060 |
Why?
|
Survival Analysis | 3 | 2021 | 10075 | 0.060 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2009 | 952 | 0.060 |
Why?
|
Female | 24 | 2024 | 392485 | 0.060 |
Why?
|
International Classification of Diseases | 1 | 2009 | 909 | 0.060 |
Why?
|
Aged | 16 | 2024 | 169179 | 0.050 |
Why?
|
Cerebral Hemorrhage | 1 | 2004 | 2656 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2018 | 64645 | 0.050 |
Why?
|
Adult | 16 | 2024 | 221122 | 0.050 |
Why?
|
Male | 19 | 2024 | 360621 | 0.050 |
Why?
|
Advance Care Planning | 1 | 2009 | 696 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4227 | 0.050 |
Why?
|
Cohort Studies | 5 | 2014 | 41440 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2010 | 4108 | 0.050 |
Why?
|
Decision Making | 2 | 2012 | 3929 | 0.050 |
Why?
|
International Agencies | 2 | 2012 | 243 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2811 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 154 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2004 | 3048 | 0.050 |
Why?
|
Peptides | 1 | 2013 | 4342 | 0.050 |
Why?
|
Immunomagnetic Separation | 1 | 2000 | 79 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39108 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6473 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 229 | 0.040 |
Why?
|
Neurosurgical Procedures | 1 | 2010 | 2071 | 0.040 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2644 | 0.040 |
Why?
|
Keratins | 1 | 2000 | 497 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 679 | 0.040 |
Why?
|
Pyridines | 1 | 2010 | 2870 | 0.040 |
Why?
|
Macrophages | 1 | 2013 | 5768 | 0.040 |
Why?
|
Cause of Death | 1 | 2008 | 3685 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 14665 | 0.040 |
Why?
|
Exanthema | 1 | 2021 | 504 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 36430 | 0.030 |
Why?
|
Retrospective Studies | 6 | 2023 | 80575 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 4567 | 0.030 |
Why?
|
Disease Progression | 3 | 2022 | 13500 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12450 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2012 | 18234 | 0.030 |
Why?
|
Biopsy | 1 | 2006 | 6768 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1551 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2023 | 1469 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 1999 | 1600 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1231 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2013 | 210 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15262 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2014 | 6815 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3824 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2013 | 346 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 1999 | 1994 | 0.020 |
Why?
|
Procarbazine | 1 | 2011 | 172 | 0.020 |
Why?
|
Lomustine | 1 | 2011 | 60 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20092 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2007 | 10203 | 0.020 |
Why?
|
Aged, 80 and over | 5 | 2014 | 58946 | 0.020 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 176 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2016 | 938 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2004 | 1833 | 0.020 |
Why?
|
Autopsy | 1 | 2013 | 1006 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2007 | 20555 | 0.020 |
Why?
|
Young Adult | 5 | 2014 | 59196 | 0.020 |
Why?
|
Vincristine | 1 | 2011 | 1036 | 0.020 |
Why?
|
Algorithms | 1 | 2009 | 14025 | 0.020 |
Why?
|
Necrosis | 1 | 2012 | 1605 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2853 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 546 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1533 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1674 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 557 | 0.020 |
Why?
|
Diagnostic Imaging | 2 | 2012 | 3531 | 0.020 |
Why?
|
Blood Vessels | 1 | 2012 | 1113 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3806 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10191 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1624 | 0.020 |
Why?
|
Piperidines | 1 | 2014 | 1657 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2012 | 2898 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 4850 | 0.010 |
Why?
|
Gene Deletion | 1 | 2012 | 2667 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 3590 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6086 | 0.010 |
Why?
|
Adolescent | 4 | 2014 | 88305 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 7238 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2804 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2012 | 2203 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5866 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4000 | 0.010 |
Why?
|
Age of Onset | 1 | 2009 | 3303 | 0.010 |
Why?
|
Animals | 2 | 2012 | 168388 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 10764 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2010 | 1906 | 0.010 |
Why?
|
Bone Marrow | 2 | 2000 | 2909 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10431 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 9180 | 0.010 |
Why?
|
Communication | 1 | 2009 | 3870 | 0.010 |
Why?
|
Palliative Care | 1 | 2009 | 3592 | 0.010 |
Why?
|
Cell Separation | 1 | 2000 | 1722 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2010 | 7852 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2000 | 946 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 1999 | 1669 | 0.010 |
Why?
|
Quality of Life | 1 | 2013 | 13355 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15879 | 0.010 |
Why?
|
Prospective Studies | 1 | 2013 | 54405 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13446 | 0.000 |
Why?
|
Hematologic Neoplasms | 1 | 1999 | 1896 | 0.000 |
Why?
|
Mice | 1 | 2012 | 81474 | 0.000 |
Why?
|